William Ward, DO
Pulmonary Disease · Abington, PANPI 1023093432
Payments from drug & device makers
Across 30 payments — averaging $147.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Genentech USA, Inc.$74
- GSK$69
- AstraZeneca$47
- Abiomed$45
- Mallinckrodt Enterprises LLC$31
- plus $189 from 11 others
What the payments were for
- Travel & lodging$86420%
- Food & beverage$54412%
- Education$3,01868%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,970 |
| Genentech USA, Inc. | 4 | $74 |
| GSK | 4 | $69 |
| AstraZeneca | 2 | $47 |
| Abiomed | 1 | $45 |
| Mallinckrodt Enterprises LLC | 1 | $31 |
| Merck | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
| Covidien LP | 1 | $16 |
| Organogenesis Inc. | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$845
How this compares
$4,426 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $199,299 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $114,874 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $65,486 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $61,796 |
| Spiriva HandihalerTiotropium Bromide | 38 | $31,767 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $23,321 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $16,531 |
| Spiriva RespimatTiotropium Bromide | 14 | $14,042 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $13,287 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 58 | $6,554 |
| Arnuity ElliptaFluticasone Furoate | 19 | $6,283 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 175 | $6,074 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $4,118 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,968 |
| AsmanexMometasone Furoate | 14 | $2,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $69 | $271,761423 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $20 | $213,34127 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $47 | $29,81879 claims |
| MerckAsmanex | $25 | $2,90914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Abington
- Richard FriedenheimAbington$631K
- Paul DorinskyAbington$154K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.